Search results :

Darifenacin

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: G04BD10

Side effects

Options: Show MedDRA Preferred Terms

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8
Dry mouth 0% - 35.3% 0% - 8.66% x x x x x x x x
Constipation 0.593% - 21.3% 0.258% - 7.87% x x x x x x x x
Headache 4.45% - 6.72% 5.41% - 5.51% x x x x x x x x
Urinary tract infection 3.73% - 4.75% 2.58% - 3.15% x x x x x x x x
Dyspepsia 2.67% - 8.38% 1.57% - 2.58% x x x x x x x x
Respiratory tract infection 2.67% - 5.09% 6.7% x
Abdominal pain 2.37% - 3.89% 0.515% x x x x x x x x
Accidental injury 2.99% 2.36% x x x x x x x
Nausea 1.5% - 4.1% 1.55% - 1.57% x x x x x x x x
Diarrhoea 2.1% x x x x x x x x
Influenza 2.08% - 2.99% 2.36% - 2.58% x x x x x x x
Back pain 1.5% - 2.37% 3.09% x x x x x x x
Pharyngitis 1.2% - 2.67% 2.32% x x x x x x x
Dry eye 1.48% - 2.1% 0.515% x x x x x x x x
Dizziness 0.89% - 2.1% 1.29% x x x x x x x x
Asthenia uncommon, 1.48% - 2.69% 1.29% x x x x x x x x
Oedema uncommon x x
Hypertension uncommon x x x x x x x x
Urinary tract disorder uncommon x x x x x x x x
Vaginal inflammation uncommon x x x x x x x x
Urinary retention uncommon x x x
Oedema peripheral uncommon x x x x x x x x
Aspartate aminotransferase increased uncommon x x
Alanine aminotransferase increased uncommon x x
Bladder pain uncommon x x
Thinking abnormal uncommon x x
Erectile dysfunction uncommon x x
Face oedema uncommon x x
Insomnia uncommon x x
Airway obstruction NOS postmarketing x x
Anaphylactic shock postmarketing x
Angioedema postmarketing x x x x x x x
Confusional state postmarketing x x x x x
Erythema multiforme postmarketing x
Hallucination postmarketing x x x x x x
Hypersensitivity postmarketing x x x x x x x
Palpitations postmarketing x x x
Syncope postmarketing x
Granuloma annulare postmarketing x
Somnolence postmarketing x x x
Arthralgia x x x x x x x
Mental disorder x
Breast disorder x
Bronchitis x x x x x x x
Infection x x
Cough x
Dysgeusia x x
Dyspnoea x
Rash x x x x x x x x
Eye disorder x
Flatulence x x
Gallbladder disorder x
Gastrointestinal disorder x
Hyperhidrosis x
Mediastinal disorder x
Nervous system disorder x
Pain x x x x x x
Pruritus x x x x x x x x
Rhinitis x x x x x x x x
Sinusitis x x x x x x x
Ulcerative stomatitis x
Cerebrovascular accident x x x x x x
Sweating x
Tachycardia x
Angiopathy x
Vomiting x x x x x x x
Weight increased x x x x x x x
Mouth ulceration x
Dry skin x x x x x x x x
Unspecified disorder of skin and subcutaneous tissue x
Nasal dryness x
Acute retention of urine x x x x x x
Vision blurred x
Depressed mood x
Constipation chronic x x x x x
Visual disturbance x
Cough increased x
Infestation NOS x
Flu symptoms x
Abnormal vision x x x x x x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

DARIFENACIN HYDROBROMIDE / ENABLEX

Side effects:33
Source:FDA

darifenacin / Enablex

Side effects:38
Source:FDA

DARIFENACIN HYDROBROMIDE / ENABLEX

Side effects:37
Source:FDA

DARIFENACIN

Side effects:38
Source:FDA Structured Product Label

DARIFENACIN

Side effects:39
Source:FDA Structured Product Label

DARIFENACIN

Side effects:42
Source:FDA Structured Product Label

DARIFENACIN (DARIFENACIN HYDROBROMIDE) / ENABLEX

Side effects:51
Source:Health Canada

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label